Is it appropriate to initiate testosterone replacement therapy in a 59-year-old male with low libido, normal Prostate-Specific Antigen (PSA) levels, and low-normal total testosterone and free testosterone levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Starting testosterone therapy for this 59-year-old male with low libido may not be appropriate based on the laboratory values provided, as his total testosterone level of 368 ng/dL and free testosterone of 5.0 ng/dL are within normal limits for his age. According to the American College of Physicians (ACP) guideline on testosterone treatment in adult men with age-related low testosterone 1, the decision to initiate testosterone treatment should be based on a discussion of the potential benefits, harms, costs, and patient's preferences, particularly in men with sexual dysfunction who want to improve sexual function. The guideline suggests that clinicians consider intramuscular rather than transdermal formulations when initiating testosterone treatment to improve sexual function in men with age-related low testosterone, as costs are considerably lower for the intramuscular formulation and clinical effectiveness and harms are similar 1.

Before initiating testosterone replacement therapy, it would be essential to rule out other causes of decreased libido, such as:

  • Depression
  • Stress
  • Relationship issues
  • Other medications
  • Medical conditions If testosterone therapy is being considered despite these borderline values, a trial of testosterone gel or testosterone cypionate injections could be considered, with careful discussion of potential risks, including:
  • Cardiovascular effects
  • Polycythemia
  • Sleep apnea exacerbation
  • Prostate issues The low PSA (0.4 ng/mL) is reassuring regarding prostate health, but monitoring would still be necessary if therapy is initiated. Testosterone therapy should be accompanied by follow-up testing of testosterone levels, complete blood count, and PSA at 3-6 month intervals initially, then annually, as recommended by the ACP guideline 1. Non-hormonal approaches to improving libido should be explored first given his borderline testosterone values.

From the Research

Testosterone Therapy Considerations

  • The patient's testosterone serum level is 368, and free testosterone is 5.0, which may not be considered low enough to initiate testosterone therapy, as the normal range for total testosterone is typically between 300-1000 ng/dL 2.
  • The patient's PSA level is 0.4, which is within normal limits, but it is essential to monitor PSA levels during testosterone therapy due to the potential risk of increasing prostate-specific antigen levels 2, 3.
  • The patient's complaint of low libido may be a symptom of hypogonadism, but other causes should be ruled out before initiating testosterone therapy 2, 4.
  • Testosterone therapy may improve libido, mood, and overall well-being, but the benefits and risks should be carefully considered, and patients should be counseled on the potential risks, including cardiovascular complications and polycythemia 2, 3, 5.

Initiating Testosterone Therapy

  • According to the guidelines, testosterone therapy should be initiated only after two morning total serum testosterone measurements show decreased levels 2.
  • The patient's current testosterone levels do not seem to be significantly low, and other factors contributing to low libido should be investigated before starting testosterone therapy 4, 6.
  • If testosterone therapy is initiated, the patient should be monitored regularly to ensure testosterone levels rise appropriately, clinical improvement occurs, and no complications develop 2, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Testosterone Therapy: Review of Clinical Applications.

American family physician, 2017

Research

Testosterone treatments: why, when, and how?

American family physician, 2006

Research

Testosterone therapy--what, when and to whom?

The aging male : the official journal of the International Society for the Study of the Aging Male, 2004

Research

Testosterone therapy: Prescribing and monitoring patterns of practice in British Columbia.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.